To determine the efficacy of Dapagliflozin and its effect on HbA1c in Type 2 Diabetic patients.

We had conducted our descriptive study in the outdoor patient department of Holy Family Hospital, Rawalpindi. Hundred, Type 2 diabetic patients of both genders were enrolled through consecutive sampling to assess the efficacy of Dapagliflozin, an SGLT2 inhibitor in a Pakistani population. Those patients with HbA1c of ≥ 7% who had fulfilled our inclusion criteria were given Dapagliflozin 10mg as either monotherapy or add-on therapy. HbA1c, BP, and body weight were noted at the start of drug therapy and after 12 weeks of drug use. The primary endpoint was ≥ a 10% relative percentage reduction of HbA1c after 12 weeks.

Out of 100 subjects there were 40 males and 60 females in our sample. The average age of the patients was 49.37±11.38 years. Dapagliflozin was given as a monotherapy to only two patients and others as an add on the drug. The average relative percent reduction after 12 weeks of treatment in HbA1c was 11.68±6.20. The sample results showed that the drug Dapagliflozin is effective for 62% of patients hence based on the sample results we conclude that the Dapagliflozin is effective against type 2 diabetics in our population for at least 53% of patients with a p-value of 0.034.

Over the period of 12 weeks, Dapagliflozin has shown a significant reduction in HbA1c and body weight of Type 2 diabetics in the Pakistani population. Once-daily dosing and a low rate of hypoglycemia make it a cost-effective and safe drug as well.